Higher CGM-derived time in range is associated with lower odds of diabetic kidney diseaseHigher time in range from glucose monitors linked to kidney health

This meta-analysis evaluated the relationship between continuous glucose monitoring (CGM) metrics and renal outcomes in a large cohort of 7182 adults with type 1 or type 2 diabetes. The study specifically focused on the association between time in range (TIR) and the development or progression of diabetic kidney disease (DKD), which includes outcomes such as albuminuria, eGFR decline, or a composite nephropathy endpoint. The analysis aimed to determine if glycemic stability, as measured by CGM-derived TIR, serves as a meaningful indicator for renal health in patients with both type 1 and type 2 diabetes.

The primary analysis assessed the odds of DKD per 10% increment in TIR. The results indicated a lower odds of DKD per 10% TIR increment, with an effect size of 0.89 (95% CI 0.84-0.95; P = 0.002). This suggests that higher levels of time in range are associated with a statistically significant reduction in the odds of developing renal complications.

To further refine the association and account for the confounding effects of average glycemia, the researchers conducted an analysis of the association between TIR and DKD adjusted for HbA1c. This adjusted analysis yielded an effect size of 0.91 (95% CI 0.86-0.97; P = 0.015). The use of the GRADE framework for the adjusted subgroup showed no detectable residual heterogeneity (I2 = 0%), suggesting a consistent association between TIR and renal outcomes independent of HbA1c levels.

Safety and tolerability data were not reported for the population in this meta-analysis. Consequently, no specific adverse event rates, serious adverse events, or discontinuation rates were provided for the use of CGM-derived metrics in this context.

While these findings provide a strong association between glucose stability and renal outcomes, they must be interpreted with caution. The study notes that the sample size for the HbA1c-adjusted subgroup was small, which may limit the strength of the inference for that specific subset. Furthermore, the analysis highlights a lack of prospective studies that utilize standardized CGM protocols combined with pre-specified hard kidney endpoints.

Compared to existing literature, these results provide specific quantitative evidence regarding the role of TIR in renal outcomes. However, the study emphasizes that an association does not imply causation. Clinical implications suggest that higher CGM-derived TIR may be associated with lower odds of DKD, potentially making TIR a useful metric for monitoring patients at risk for nephropathy.

Several questions remain for future investigation. Specifically, the lack of prospective, standardized trials means the exact mechanism by which TIR influences renal health remains unclear. Future research should focus on large-scale prospective studies to establish a causal link and determine if interventions specifically targeting TIR can improve outcomes for patients with diabetic kidney disease.